OR WAIT null SECS
July 31, 2017
Partnership aims to develop new vaccine regimens against hep B and HIV by combining respective proprietary vaccine technologies.
July 28, 2017
Pharma majors AstraZeneca and Merck & Co. form $8.5-billion partnership to develop cancer therapies revolving around AstraZeneca’s PARP inhibitor, Lynparza.
July 27, 2017
Pharma major aims to focus majority of R&D capital into priority therapy areas and plans to cut approximately 30 R&D programs.
Takeda Pharmaceutical partners with US biopharmaceutical company, TESARO, in deal worth up to $340 million to develop and commercialize PARP inhibitor.
July 25, 2017
Eli Lilly and Incyte face a roughly 18-month application delay for rheumatoid arthritis drug, baricitinib, in the US with a request from FDA for additional clinical data.
July 24, 2017
Manufacturing capacity will be increased by one third and approximately 300 new high-wage and highly-skilled jobs will be created at the Fremont site.
July 19, 2017
The new center will help biopharmaceutical and pharmaceutical manufacturers with product development.
GSK plans to invest in several UK manufacturing sites and to close its Slough site in conjunction with the sale of the Horlicks brand manufactured in Slough.
July 17, 2017
GSK plans to deliver up to 40 million doses of its quadrivalent flu vaccine for the 2017–2018 season.
July 12, 2017
The company has entered into a settlement agreement with generic-drug companies to resolve patent litigation.